Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Chronic Obstructive Pulmonary Disorder market report explains the definition, types, applications, major countries, and major players of the Chronic Obstructive Pulmonary Disorder market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Merck
Astellas Pharma
Roche
GSK
Novartis
Aquinox Pharmaceuticals
AstraZeneca
Ache
Almirall
Teva Pharmaceuticals
Asmacure
Ario Pharma
Boehringer Ingelheim
Pfizer
By Type:
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
By End-User:
Hospitals
Clinics
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Chronic Obstructive Pulmonary Disorder Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Chronic Obstructive Pulmonary Disorder Outlook to 2028- Original Forecasts
-
2.2 Chronic Obstructive Pulmonary Disorder Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Chronic Obstructive Pulmonary Disorder Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Chronic Obstructive Pulmonary Disorder Market- Recent Developments
-
6.1 Chronic Obstructive Pulmonary Disorder Market News and Developments
-
6.2 Chronic Obstructive Pulmonary Disorder Market Deals Landscape
7 Chronic Obstructive Pulmonary Disorder Raw Materials and Cost Structure Analysis
-
7.1 Chronic Obstructive Pulmonary Disorder Key Raw Materials
-
7.2 Chronic Obstructive Pulmonary Disorder Price Trend of Key Raw Materials
-
7.3 Chronic Obstructive Pulmonary Disorder Key Suppliers of Raw Materials
-
7.4 Chronic Obstructive Pulmonary Disorder Market Concentration Rate of Raw Materials
-
7.5 Chronic Obstructive Pulmonary Disorder Cost Structure Analysis
-
7.5.1 Chronic Obstructive Pulmonary Disorder Raw Materials Analysis
-
7.5.2 Chronic Obstructive Pulmonary Disorder Labor Cost Analysis
-
7.5.3 Chronic Obstructive Pulmonary Disorder Manufacturing Expenses Analysis
8 Global Chronic Obstructive Pulmonary Disorder Import and Export Analysis (Top 10 Countries)
-
8.1 Global Chronic Obstructive Pulmonary Disorder Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Chronic Obstructive Pulmonary Disorder Export by Region (Top 10 Countries) (2017-2028)
9 Global Chronic Obstructive Pulmonary Disorder Market Outlook by Types and Applications to 2022
-
9.1 Global Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Short-Acting Bronchodilators Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Corticosteroids Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Methylxanthines Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Long-Acting Bronchodilators Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Phosphodiesterase-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Chronic Obstructive Pulmonary Disorder Market Analysis and Outlook till 2022
-
10.1 Global Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.2.2 Canada Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.2.3 Mexico Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.2 UK Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.3 Spain Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.4 Belgium Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.5 France Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.6 Italy Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.7 Denmark Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.8 Finland Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.9 Norway Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.10 Sweden Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.11 Poland Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.12 Russia Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.3.13 Turkey Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.2 Japan Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.3 India Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.4 South Korea Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.5 Pakistan Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.6 Bangladesh Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.7 Indonesia Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.8 Thailand Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.9 Singapore Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.10 Malaysia Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.11 Philippines Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.4.12 Vietnam Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5.2 Colombia Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5.3 Chile Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5.4 Argentina Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5.5 Venezuela Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5.6 Peru Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5.7 Puerto Rico Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.5.8 Ecuador Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.6.2 Kuwait Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.6.3 Oman Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.6.4 Qatar Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.6.5 Saudi Arabia Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.6.6 United Arab Emirates Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.7.2 South Africa Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.7.3 Egypt Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.7.4 Algeria Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
-
10.8.2 New Zealand Chronic Obstructive Pulmonary Disorder Consumption (2017-2022)
11 Global Chronic Obstructive Pulmonary Disorder Competitive Analysis
-
11.1 Merck
-
11.1.1 Merck Company Details
-
11.1.2 Merck Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Merck Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.1.4 Merck Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Astellas Pharma
-
11.2.1 Astellas Pharma Company Details
-
11.2.2 Astellas Pharma Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.2.4 Astellas Pharma Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Roche
-
11.3.1 Roche Company Details
-
11.3.2 Roche Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Roche Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.3.4 Roche Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 GSK
-
11.4.1 GSK Company Details
-
11.4.2 GSK Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 GSK Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.4.4 GSK Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Novartis
-
11.5.1 Novartis Company Details
-
11.5.2 Novartis Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Novartis Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.5.4 Novartis Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Aquinox Pharmaceuticals
-
11.6.1 Aquinox Pharmaceuticals Company Details
-
11.6.2 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.6.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 AstraZeneca
-
11.7.1 AstraZeneca Company Details
-
11.7.2 AstraZeneca Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 AstraZeneca Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.7.4 AstraZeneca Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Ache
-
11.8.1 Ache Company Details
-
11.8.2 Ache Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Ache Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.8.4 Ache Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Almirall
-
11.9.1 Almirall Company Details
-
11.9.2 Almirall Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Almirall Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.9.4 Almirall Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Teva Pharmaceuticals
-
11.10.1 Teva Pharmaceuticals Company Details
-
11.10.2 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.10.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Asmacure
-
11.11.1 Asmacure Company Details
-
11.11.2 Asmacure Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Asmacure Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.11.4 Asmacure Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Ario Pharma
-
11.12.1 Ario Pharma Company Details
-
11.12.2 Ario Pharma Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Ario Pharma Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.12.4 Ario Pharma Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Boehringer Ingelheim
-
11.13.1 Boehringer Ingelheim Company Details
-
11.13.2 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.13.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Pfizer
-
11.14.1 Pfizer Company Details
-
11.14.2 Pfizer Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Pfizer Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
11.14.4 Pfizer Chronic Obstructive Pulmonary Disorder Product Portfolio
-
11.14.5 Recent Research and Development Strategies
12 Global Chronic Obstructive Pulmonary Disorder Market Outlook by Types and Applications to 2028
-
12.1 Global Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Short-Acting Bronchodilators Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Methylxanthines Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Long-Acting Bronchodilators Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Phosphodiesterase-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Chronic Obstructive Pulmonary Disorder Market Analysis and Outlook to 2028
-
13.1 Global Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.2.2 Canada Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.2.3 Mexico Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.2 UK Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.3 Spain Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.4 Belgium Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.5 France Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.6 Italy Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.7 Denmark Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.8 Finland Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.9 Norway Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.10 Sweden Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.11 Poland Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.12 Russia Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.3.13 Turkey Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.2 Japan Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.3 India Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.4 South Korea Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.8 Thailand Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.9 Singapore Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.11 Philippines Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5.2 Colombia Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5.3 Chile Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5.4 Argentina Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5.6 Peru Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.6.3 Oman Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.6.4 Qatar Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.7.2 South Africa Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.7.3 Egypt Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.7.4 Algeria Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Chronic Obstructive Pulmonary Disorder Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Chronic Obstructive Pulmonary Disorder
-
Figure of Chronic Obstructive Pulmonary Disorder Picture
-
Table Global Chronic Obstructive Pulmonary Disorder Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Chronic Obstructive Pulmonary Disorder Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Short-Acting Bronchodilators Consumption and Growth Rate (2017-2022)
-
Figure Global Corticosteroids Consumption and Growth Rate (2017-2022)
-
Figure Global Methylxanthines Consumption and Growth Rate (2017-2022)
-
Figure Global Long-Acting Bronchodilators Consumption and Growth Rate (2017-2022)
-
Figure Global Phosphodiesterase-4 Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Table North America Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Figure United States Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Canada Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Mexico Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Table Europe Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Figure Germany Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure UK Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Spain Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Belgium Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure France Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Italy Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Denmark Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Finland Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Norway Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Sweden Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Poland Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Russia Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Turkey Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Table APAC Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Figure China Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Japan Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure India Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure South Korea Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Thailand Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Singapore Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Philippines Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Table South America Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Figure Brazil Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Colombia Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Chile Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Argentina Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Peru Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Table GCC Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Figure Bahrain Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Oman Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Qatar Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Table Africa Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Figure Nigeria Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure South Africa Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Egypt Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure Algeria Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Table Oceania Chronic Obstructive Pulmonary Disorder Consumption by Country (2017-2022)
-
Figure Australia Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Chronic Obstructive Pulmonary Disorder Consumption and Growth Rate (2017-2022)
-
Table Merck Company Details
-
Table Merck Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Merck Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Astellas Pharma Company Details
-
Table Astellas Pharma Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Astellas Pharma Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Roche Company Details
-
Table Roche Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Roche Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table GSK Company Details
-
Table GSK Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table GSK Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table GSK Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Novartis Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Aquinox Pharmaceuticals Company Details
-
Table Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table AstraZeneca Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Ache Company Details
-
Table Ache Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ache Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Ache Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Almirall Company Details
-
Table Almirall Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Almirall Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Almirall Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Teva Pharmaceuticals Company Details
-
Table Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Asmacure Company Details
-
Table Asmacure Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Asmacure Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Asmacure Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Ario Pharma Company Details
-
Table Ario Pharma Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ario Pharma Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Ario Pharma Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Chronic Obstructive Pulmonary Disorder Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Chronic Obstructive Pulmonary Disorder Main Business and Markets Served
-
Table Pfizer Chronic Obstructive Pulmonary Disorder Product Portfolio
-
Figure Global Short-Acting Bronchodilators Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Methylxanthines Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Long-Acting Bronchodilators Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Phosphodiesterase-4 Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Table North America Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Figure United States Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Figure Germany Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Figure China Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Figure Brazil Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Chronic Obstructive Pulmonary Disorder Consumption Forecast by Country (2022-2028)
-
Figure Australia Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Chronic Obstructive Pulmonary Disorder Consumption Forecast and Growth Rate (2022-2028)
-
